MX2009007139A - Metodos y vectores para generar inmunoglobulinas no sialiladas. - Google Patents

Metodos y vectores para generar inmunoglobulinas no sialiladas.

Info

Publication number
MX2009007139A
MX2009007139A MX2009007139A MX2009007139A MX2009007139A MX 2009007139 A MX2009007139 A MX 2009007139A MX 2009007139 A MX2009007139 A MX 2009007139A MX 2009007139 A MX2009007139 A MX 2009007139A MX 2009007139 A MX2009007139 A MX 2009007139A
Authority
MX
Mexico
Prior art keywords
asialylated
immunoglobulins
vectors
generating
methods
Prior art date
Application number
MX2009007139A
Other languages
English (en)
Inventor
Bernard Scallon
T Shantha Raju
Susan Tam
Michael Naso
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of MX2009007139A publication Critical patent/MX2009007139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Abstract

Las propiedades de una proteína que contiene Fc, por ejemplo un anticuerpo, se controlan alterando la sialilación de los oligosacáridos de la región Fc, transfectando la línea celular que expresa la proteína que contiene Fc con una secuencia de vector que codifica una sialidasa; las proteínas que contienen Fc modificadas tienen utilidad terapéutica en enfermedades o condiciones en las que es deseable controlar la afinidad por uno o más de los receptores Fc?RI, Fc?RIIA y Fc?RIIIA, la actividad de ADCC, la activación de macrófagos o monocitos, la vida media en el suero, y la avidez.
MX2009007139A 2006-12-28 2007-12-26 Metodos y vectores para generar inmunoglobulinas no sialiladas. MX2009007139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88230106P 2006-12-28 2006-12-28
PCT/US2007/088809 WO2008083150A2 (en) 2006-12-28 2007-12-26 Methods and vectors for generating asialylated immunoglobulins

Publications (1)

Publication Number Publication Date
MX2009007139A true MX2009007139A (es) 2009-10-08

Family

ID=39589190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007139A MX2009007139A (es) 2006-12-28 2007-12-26 Metodos y vectores para generar inmunoglobulinas no sialiladas.

Country Status (12)

Country Link
US (3) US8540992B2 (es)
EP (1) EP2115151B1 (es)
JP (1) JP2010514448A (es)
KR (1) KR101667981B1 (es)
CN (2) CN101646775B (es)
BR (1) BRPI0720861A2 (es)
CA (1) CA2674239C (es)
DK (1) DK2115151T3 (es)
ES (1) ES2474940T3 (es)
MX (1) MX2009007139A (es)
RU (1) RU2466189C2 (es)
WO (1) WO2008083150A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002562A1 (en) * 2010-06-30 2012-01-05 Tokyo University Of Science Educational Foundation Administrative Organization Modified protein therapeutics
AU2012204241A1 (en) * 2011-01-06 2013-06-06 The Johns Hopkins University Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
EP2702077A2 (en) * 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2692539T3 (es) * 2011-12-19 2018-12-04 The Rockefeller University Polipéptidos antiinflamatorios no sialilados
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) * 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
EP3572090B1 (en) * 2012-12-24 2022-12-14 Coagulant Therapeutics Corporation Short-acting factor vii polypeptides
ES2755181T3 (es) 2013-02-13 2020-04-21 Lab Francais Du Fractionnement Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
CN105263960B (zh) * 2013-04-18 2020-05-22 国家医疗保健研究所 具有降低的免疫原性的组合物
CA2910877C (en) * 2013-05-03 2021-08-03 Fujifilm Diosynth Biotechnologies Uk Limited Expression process
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104004727B (zh) * 2014-06-09 2016-02-17 东北师范大学 一种具有唾液酸水解酶活性的蛋白质的制备方法
JP2017528468A (ja) * 2014-09-10 2017-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ガラクトース操作型免疫グロブリン１抗体
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP2018500934A (ja) 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
TWI717333B (zh) * 2015-01-30 2021-02-01 中央研究院 增進抗體功效之通用糖型組合物及方法
CN107847586A (zh) 2015-03-04 2018-03-27 洛克菲勒大学 抗炎多肽
KR102512608B1 (ko) * 2016-01-15 2023-03-22 버클리 라잇츠, 인크. 환자 특이적인 항암 치료제의 제조 방법 및 그 치료 방법
PL3512876T3 (pl) * 2016-09-13 2022-02-14 Coagulant Therapeutics Corporation Glikoformy czynnika viia
WO2018092078A1 (en) * 2016-11-18 2018-05-24 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN108956979B (zh) * 2018-08-02 2021-07-27 上海细胞治疗集团有限公司 一种细胞毒性检测试剂组合
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
JP7343890B2 (ja) * 2019-04-26 2023-09-13 国立大学法人東海国立大学機構 シアリダーゼ活性を有する酵素剤及びその利用
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
WO2024079711A1 (en) 2022-10-14 2024-04-18 Janssen Research & Development, Llc Method for detection of antibody-dependent cellular phagocytosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2726898B2 (ja) 1988-05-02 1998-03-11 丸金醤油株式会社 ノイラミニダーゼ・アイソザイムｌ及びガングリオシド類の製造法
ES2340112T3 (es) * 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
CN1505682A (zh) * 2000-06-26 2004-06-16 ��ѧ�о��� 用于同时糖化发酵的方法和组合物
JP2006507228A (ja) 2002-07-01 2006-03-02 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 応答性の細胞、組織および器官を保護、回復ならびに増強するための組換え型組織保護サイトカインおよびそれをコードする核酸
CN1729013B (zh) 2002-11-22 2012-10-03 耐百生物制药有限公司 广谱抗病毒化合物、药物制剂及其用途
US7785594B2 (en) * 2003-08-14 2010-08-31 Life Sciences Research Partners Vzw Factor VIII inhibitory antibodies with reduced glycosylation

Also Published As

Publication number Publication date
RU2466189C2 (ru) 2012-11-10
CN105056231A (zh) 2015-11-18
BRPI0720861A2 (pt) 2014-02-25
US20140057319A1 (en) 2014-02-27
CA2674239A1 (en) 2008-07-10
EP2115151A4 (en) 2011-01-26
RU2009128960A (ru) 2011-02-10
CN101646775B (zh) 2016-08-24
DK2115151T3 (en) 2015-01-05
ES2474940T3 (es) 2014-07-10
KR101667981B1 (ko) 2016-10-20
US20100172911A1 (en) 2010-07-08
KR20090096740A (ko) 2009-09-14
WO2008083150A3 (en) 2009-04-30
JP2010514448A (ja) 2010-05-06
US8975040B2 (en) 2015-03-10
CA2674239C (en) 2018-01-23
US8540992B2 (en) 2013-09-24
US20150291946A1 (en) 2015-10-15
WO2008083150A2 (en) 2008-07-10
EP2115151B1 (en) 2014-05-07
EP2115151A2 (en) 2009-11-11
CN101646775A (zh) 2010-02-10

Similar Documents

Publication Publication Date Title
MX2009007139A (es) Metodos y vectores para generar inmunoglobulinas no sialiladas.
SG163548A1 (en) Methods and compositions with enhanced therapeutic activity
Giddens et al. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody
Jürgensen et al. A novel functional role of collagen glycosylation: interaction with the endocytic collagen receptor uparap/ENDO180
Wei et al. Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation
Ihanus et al. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4
BR112015017778A2 (pt) anticorpos que compreendem domínios constantes quiméricos, moléculas de ácido nucleico, vetor, célula e proteína de fusão do receptor fc
CO6491105A2 (es) Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada
Hatherley et al. The CD200 and CD200 receptor cell surface proteins interact through their N‐terminal immunoglobulin‐like domains
Jung et al. Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: direct evidence obtained with dimeric GPVI-specific Fabs
ECSP066603A (es) Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas
Tamm et al. The IgG Binding Site of Human FcγRIIIB Receptor Involves CC′ and FG Loops of the Membrane-proximal Domain (∗)
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
PL415463A1 (pl) Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
MX2013007392A (es) Anticuerpo modificado con vida media mejorada.
BR112013002074A2 (pt) proteínas de fusão de fragmentos de proteína humana natural para criar composições de fc de imunoglobulina multimerizada ordenadamente
TW200720439A (en) Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
Fellmann et al. High affinity targeting of CD23 inhibits IgE synthesis in human B cells
Lecoanet‐Henchoz et al. Mouse CD23 regulates monocyte activation through an interaction with the adhesion molecule CD11b/CD18
Feng et al. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
MX2020007882A (es) Variantes fc con unión mejorada a fcrn y semivida prolongada.
Bradley et al. Effect of the GPI anchor of human Thy-1 on antibody recognition and function
Kums et al. Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins
Seitz et al. Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

Legal Events

Date Code Title Description
FG Grant or registration